Publication
Road to COP29: Our insights
The 28th Conference of the Parties on Climate Change (COP28) took place on November 30 - December 12 in Dubai.
It is always a bit of a challenge to write a new and fresh introduction to the International Restructuring Newswire. So, for this issue, I decided to seek help from Copilot, the new AI-powered chat mode of Microsoft. Given the profession of many of our readers, I asked Copilot: “what are the prospects for business financial restructuring professionals given the strong US economy coupled with the geopolitical problems around the world?” I really didn’t know what kind of answer to get from our AI friend—but you can judge for yourself:
While the strong economy provides opportunities, geopolitical complexities demand vigilance. Business financial restructuring professionals must stay informed, anticipate risks, and navigate uncertainty. Their role extends beyond numbers—it’s about safeguarding businesses in a dynamic world. Remember, adaptability and foresight are their compass in uncharted waters. – [citing to a KPMG article]
Not bad, but pretty generic and obvious. We offer something different in this issue: articles providing specific analysis of recent developments in the cross-border restructuring world from our lawyers in the US, UK, Netherlands and Canada. Not to shame my friend at Copilot, but I would think the information in these articles will be of greater value as you face real problems in the nonvirtual restructuring world.
I trust that you will agree . . .
Good reading,
Howard Seife
Global Co-Head of Restructuring
New York
Scott Atkins
Global Co-Head of Restructuring
Sydney
Publication
The 28th Conference of the Parties on Climate Change (COP28) took place on November 30 - December 12 in Dubai.
Publication
Miranda Cole, Julien Haverals and Emma Clarke of our Brussels/ London offices are the authors of a chapter on procedural issues in merger control that has been published in the third edition of the Global Competition Review’s The Guide to Life Sciences. This covers a number of significant procedural developments that have affected merger review of life sciences transactions.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023